Related Experiment Video
Updated: Jul 5, 2026
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
Somatostatin in inflammatory bowel disease
1Department of Gastroenterology/Internal Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Mediators of Inflammation
|January 1, 1997
Summary
Neuropeptides influence intestinal immunity, impacting inflammatory bowel disease (IBD) development. Somatostatin, a key inhibitory peptide, may play a crucial role in managing IBD pathogenesis.
Area of Science:
- Immunology
- Neurogastroenterology
- Molecular Biology
Background:
- Intestinal inflammation involves complex interactions between immunomodulating cells and molecular mediators.
- Neuropeptides, released by neural and neuroendocrine cells, modulate both systemic and intestinal immune responses.
- Evidence suggests neuropeptides are implicated in the pathogenesis of inflammatory bowel disease (IBD).
Purpose of the Study:
- To explore the role of neuropeptides in the immune system.
- To investigate the involvement of neuropeptides in the pathogenesis of inflammatory bowel disease (IBD).
- To discuss the specific function of somatostatin as an anti-inflammatory peptide in IBD.
Main Methods:
- Review of existing morphological and experimental evidence on neuropeptide involvement in IBD.
- Analysis of the immunomodulatory functions of neuropeptides.
- Discussion of somatostatin's inhibitory role in inflammatory processes.
Main Results:
- Neuropeptides exhibit both pro-inflammatory and anti-inflammatory activities.
- Significant evidence supports the involvement of neuropeptides in IBD pathogenesis.
- Somatostatin is identified as a primary peptide with inhibitory effects on inflammation.
Conclusions:
- Neuropeptides are critical regulators of intestinal immunity and inflammation.
- The role of neuropeptides, particularly somatostatin, warrants further investigation in IBD.
- Understanding neuropeptide function may offer new therapeutic strategies for IBD.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...